GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD
In patients with IBD, GLP-1 receptor agonists are effective for weight loss and associated with few episodes of disease exacerbation.
Authors
- William Schreiber-Stainthorp (ORCID: https://orcid.org/0000-0002-7386-8754)
- Irving Levine (ORCID: https://orcid.org/0000-0003-4922-1835)
- Shaina Sekhri (ORCID: https://orcid.org/0000-0001-8691-9955)
- Olivia Delau
- Jordan E. Axelrad (ORCID: https://orcid.org/0000-0003-1951-7790)
- Xucong Meng
- M. F. S. El-Hawary
- Krutika Pandit
- Brandon Locke
Institutions
- NYU Langone Health (US)
- Hinge Health (US)
- New York University (US)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1093/ibd/izae250
- Citations
- 19
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.80
Funders
- Crohn's and Colitis Foundation
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases